VivoSeq
Other

Motor Neuron Disease

7

Pipeline Programs

1

Active Trials

6

Companies Involved

Motor Neuron Disease is an early-stage landscape with 7 programs across 6 companies. The most active players are Flex Pharma, Inc., Roche, UCB.

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

80/100

Attrition Rate

14/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Trial Status

7

clinical trials

Completed4 · 57%
Terminated1 · 14%
Unknown status1 · 14%
Recruiting1 · 14%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)